<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136604</url>
  </required_header>
  <id_info>
    <org_study_id>104727 (Booster - 15-24 mths)</org_study_id>
    <secondary_id>104730</secondary_id>
    <nct_id>NCT00136604</nct_id>
  </id_info>
  <brief_title>Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m &amp; Mencevax ACWY at 24-30m</brief_title>
  <official_title>Assess Immunogenicity, Safety &amp; Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC at 15-24 m &amp; of a Dose of Mencevax™ ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix™-HepB/Hib-MenAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a
      booster dose of DTPw-HBV/Hib-MenAC compared to DTPw-HBV/Hib given to healthy subjects at 15
      to 24 months of age primed with 3 doses of Tritanrix™-HepB/Hib-MenAC in study 100480.
      Antibody persistence will be evaluated at 24 to 30 months. Immunogenicity, safety and
      reactogenicity of a dose of Mencevax™ ACWY given at 24 to 30 months will also be evaluated
      when given to subjects not boosted with a MenA conjugate and/or MenC containing vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two stages. In the DTP booster phase subjects will receive a
      booster dose of Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hib (active control) at 15 to 24
      months in a single-blind manner so that the subjects' parents will not know which vaccine was
      administered to their child (this booster phase is no longer recruiting). In the Mencevax™
      ACWY phase at 24-30 months a dose of Mencevax™ ACWY will be given to subjects who were not
      boosted with a MenA conjugate and/or MenC containing vaccine at 15-24 months in an open
      manner (this booster phase is not yet recruiting). Up to four blood samples will be taken:
      before and one month after the administration of the DTP booster dose and of Mencevax™ ACWY.
      To comply with the immunisation calender of Thailand, at 15-24 months all subjects will
      receive OPV. At 16-25 months 2 doses of Japanese Encephalitis (JE) vaccine or a dose of
      varicella vaccine will be offered and at 25-31 months a dose of varicella or JE vaccine will
      be offered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1M post 4th dose of study vaccine &amp; applicable control: SBA-MenC/A≥128, anti-PRP≥1. 1M post Mencevax booster in subjects primed with MenAC conjugate: SBA-MenC/A≥128.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre and 1M post each vacc dose: antibody conc or titer, seroprot, seropos and/or vacc response to all antigens administered. Loc/gen symp: D 0-3, unsol symp: D 0-30 post each vac. SAE for entire study.</measure>
  </secondary_outcome>
  <enrollment type="Actual">617</enrollment>
  <condition>Whole Cell Pertussis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Hepatitis B</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria-tetanus-pertussis-hep B/Hib-meningococcal A&amp;C</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male or female between and including 15 and 24 months of age

          -  Having participated in the primary vaccination study DTPW-HBV=HIB-MENAC-TT-003 (eTrack
             No. 100480)

        Exclusion criteria:

          -  Booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus
             influenzae type b (Hib) and/or meningococcal serogroups A and/or C disease not
             foreseen in the protocol, after the date of the study conclusion visit of the primary
             vaccination study DTPW-HBV=HIB-MENAC-TT-003 (eTrack No. 100480).

          -  History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B, Hib
             and/or meningococcal serogroup A or C disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures including febrile seizures (at least
             two events) in infancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>427 Days</minimum_age>
    <maximum_age>730 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct/show/NCT00317161</url>
    <description>Primary Study</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis diphtheria</keyword>
  <keyword>Hib &amp; meningococcal serogroup A &amp; C disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104727 (Booster - 15-24 mths)</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104727 (Booster - 15-24 mths)</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104727 (Booster - 15-24 mths)</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104727 (Booster - 15-24 mths)</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104727 (Booster - 15-24 mths)</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104727 (Booster - 15-24 mths)</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>April 13, 2017</submitted>
    <returned>July 7, 2017</returned>
    <submitted>February 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

